A Standardized Plant Extract Containing a Target Compound is Acceptable as a Potent Therapeutic Entity: Relevance to BEC and Solamargine, a Topical Clinical Formulation CuradermBEC5

Aruba Cham; Kai Cham; Tania Chase; Bill Cham

doi:doi:10.11648/j.jctr.20150302.12

| Peer-Reviewed

A Standardized Plant Extract Containing a Target Compound is Acceptable as a Potent Therapeutic Entity: Relevance to BEC and Solamargine, a Topical Clinical Formulation CuradermBEC5

Aruba Cham, Kai Cham, Tania Chase, Bill Cham

Published in Journal of Cancer Treatment and Research (Volume 3, Issue 2)

Received: 26 February 2015 Accepted: 19 March 2015 Published: 24 March 2015

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

New approaches to curb developmental and end-stage production expenses, whilst generating a safe and effective treatment for cancer, resulting in lower cost for the patient and healthcare system, are warranted. A bioassay-guided fractionation of a Solanum plant, S. sodomaeum, to a standardized extract can be classified as a new drug. It is shown that a specific standardized plant extract, BEC, containing a given concentration of a target efficacious and safe compound, solamargine, is an acceptable anticancer and less costly chemotherapeutic reality.

Published in	Journal of Cancer Treatment and Research (Volume 3, Issue 2)
DOI	10.11648/j.jctr.20150302.12
Page(s)	22-27
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Cancer, Solamargine, BEC, Curaderm, Solanum, Plant Extract

References

[1]	Goozer, M. (2004) The $800 million pill: The truth behind the cost of new drugs. University of California Press. Berkley, CA.
[2]	Chataing, B., Christancho, N.B. and Usubillaga, A. (1998) Topical treatment of herpes simplex, herpes zoster and genital herpes with a mixture of Solanaceous glycoalkaloids. MedULA. Universidad de Los Andes. 7, 30-34.
[3]	Gubarev, M.I., Enioutina, E.Y., Taylor, J.L., Visic, D.M. and Daynes, I.A. (1998) Plant-derived alkaloid protects mice against lethal infection with Salmonella typhinurium. Phyt. Res. 12, 79-88.
[4]	Giron, L.M., Aguilar, G.A. Aceres, A.G. and Arroyo, G.L. (1998) Anticandidal activity of plant used for the treatment of vaginitis in Guatemala and clinical trial of Solanum nigrescences preparation. Journal Ethnopharmacology, 22, 307-313.
[5]	Cham, B.E. and Wilson, L. (1987) HPLC of glycoalkaloids from Solanum sodomaeum L. Planta Medica, 53, 59-61. Doi: 10.1055/s-2006-962612
[6]	Cham, B.E., Gilliver, M. and Wilson, L. (1987) Antitumour effects of glycoalkaloids isolated from Solanum sodomaeum L. Planta Medica, 53, 34-36. Doi: 10.1055/s-2006-962612
[7]	Cham, B.E. (2013) Drug therapy: Solamargine and other solasodine rhamnosyl glycosides as anticancer agents. Drug Therapy, 2(2), 33-49. Doi: 10.4236/mc.2013.22005
[8]	Daunter, B. and Cham, B.E. (1990) Solasodine glycosides. In vitro preferential cytotoxicity for human cancer cells. Cancer Letters, 55, 209-220. Doi: 10.1016/0304-3835(90)90121-D
[9]	Cham, B.E. and Chase, T.R. (2012) Solasodine Rhamnosyl Glycosides Cause Apoptosis in Cancer Cells. Do They Also Prime the Immune System Resulting in Long-Term Protection Against Cancer? Planta Medica, 78, 349-353. Doi: 10.1055/s-0031-1298149
[10]	He, D.J. (2006) Structure and anticancer activity of glycoalkaloids. Master’s thesis.
[11]	Lipscombe, R.J., Carter, S.J., and Ruane, M. (2005) Rhamnose binding protein. United States Patent 6, 930, 171 B2 Aug 16.
[12]	Wang, Y., Gao, J., Gu, G., Li, G., Cui, C., Sun, B., and Lou, H. (2011) In situ RBL receptor visualization and its mediated anticancer activity for solasodine rhamnosides. Chemistry Biochemistry, 12(16), 2418-2420.
[13]	Kuo, K.W., Hsu, S.H., Li, Y.P., Lin, W.L., Liu, L.F., Chang, L.C., Lin, C.C., Lin, C.N. and Sheu, H.M. (2000) Anticancer activity evaluation of the Solanum glycoalkaloid solamargine. Triggering apoptosis in human hepatoma cells. Biochemical Pharmacology, 60, 1865-1873. Doi:10.1016/S0006-2952(00)00506-2
[14]	Liang, C.H., L.F. Liu, L.Y. Shiu, Y.S. Huang, L.C. Chang and K.W. Kuo, 2004. Action of solamargine on TNFs and cisplatin-resistant human lung cancer cells. Biochem. Biophys. Res. Commun., 322(3): 751-758.
[15]	Kuo, K.W. and Lin, C.N. (1999) Pharmacological composition for treating cancer cells. United States Patent 6, 214-803.
[16]	Cham, B.E. (2000) Medicinal Composition and their Method of Preparation. Australia Patent 779512.
[17]	Cham, B.E. (2008) Cancer intralesion chemotherapy with solasodine rhamnosyl glycosides. Research Journal Biological Science, 3(9), 1008-1017.
[18]	Cham, B.E. (2007) Solasodine Rhamnosyl Glycosides Specifically Bind Cancer Cell Receptors and Induce Apoptosis and Necrosis. Treatment for Skin Cancer and Hope for Internal Cancers. Research Journal Biological Sciences, 2(4), 503-514.
[19]	Cham, B.E. and Meares, H.M. (1987) Glycoalkaloids from Solanum sodomaeum L. are effective in the treatment of skin cancers in man. Cancer Letters, 36, 111-118. Doi: 10.1016/0304-3835(87)90081-4
[20]	Chase, T.R. (2011) Curaderm BEC5 for Skin Cancers, Is It? An Overview, Journal Cancer Therapy, 2(5), 728-745. Doi: 10.4236/jct.2011.25099
[21]	Cham, B.E. (2011) Topical solasodine rhamnosyl glycosides derived from the eggplant treats large skin cancers: two case reports. International Journal Clinical Medicine, 2(4), 473-477. Doi: 10.4236/ijcm.2011.24080
[22]	Punjabi, S., Cook, L.J., Kersey, P., Marks R. and Cerio, R. (2008) Solasodine glycoalkaloids: a novel topical therapy for basal cell carcinoma. A double-blind, randomized, placebo-controlled, parallel group, multicentre study. International Journal Dermatology, 47, 78-82. Doi:10.1111/j.1365-4632.2007.03363.x
[23]	Goldberg, L.H., Landau, J.M., Moody, M.N., and Vergilis-Kalner, I.J. (2011) Treatment of Bowen’s disease on the penis with low concentration of a standard mixture of solasodine glycosides and liquid nitrogen. Dermatologic Surgery, 37, 858-861. Doi: 10.1111/j.1524-4725.2011.02014.x
[24]	Cham, B.E. (2013) Solasodine Glycosides: A Topical Therapy for Actinic Keratosis. A Single-Blind, Randomized, Placebo-Controlled, Parallel Group Study with CuradermBEC5. Journal of Cancer Therapy Vol. 2 No. 2, pp.588-596.
[25]	Cham, B.E. (2013) Topical CuradermBEC5 Therapy for Periocular Nonmelanoma Skin Cancers: A Review of Clinical Outcomes. International Journal of Clinical Medicine, Vol. 4 No. 5, pp. 233-238.
[26]	Cham, B.E. and Daunter, B. (1999) Glycoalkaloids. United States Patent 5958770.
[27]	Solbec. (2006) Investigator’s Brochure. Edition Number 6, 1-56.
[28]	Cui, C., Wen, X., Cui, M., Goa, J., Sun, B., and Lou, H. (2012) Synthesis of solasodine glycoside derivatives and evaluation of their cytotoxic effects on human cancer cells. Drug Discoveries & Therapeutics, 6(1), 9-17.
[29]	Wu, C.H., Liang, C.H., Shiu, L.Y., Chang, L.C., Lin. T.S., Lan, C.C.E., Tsai, J.C., Wong, T.W., Wei, K.J., Lin, T.X., Chang, N.S., and Sheu, H.M. (2011) Solanum incanum extract (SR-T100) induces cutaneous squamous cell carcinoma apoptosis through modulating tumour necrosis factor receptor signalling pathway. Journal Dermatological Science, 63(2), 83-92.
[30]	Shabana, M.M., Salama, M.M., Ezzat, S.M., and Ismail, L.R. (2013) In vitro and in vivo anticancer activity of the fruit peels of Solanum melongena L. against hepatocellular carcinoma. Journal Carcinogene Mutagene, 4, 149. Doi: 10.4172/2157-2518.1000149
[31]	Cham, B.E. (2013) Inspired by Nature, Proven by Science. The new generation cancer treatment that causes cancer cells to commit suicide. 1st Edition, Colorite Graphics, Vanuatu. ISBN=978-1-62951-158-0
[32]	Cham, B.E. (In preparation) CuradermBEC5 and CuradermSM2 are equivalent for human basal cell carcinomas.
[33]	Kantarjian, H.M., Fojo, T., Mathisen, M. and Zwelling, L.A. (2013) Cancer drugs in the United States: Justum Pretium – The Just Price. Journal Clinical Oncology, 31(28) 3600-3604.
[34]	CNN Money. (2010) Tanning Salons Burned by Health Care Bill. http://money.cnn.com/2010/03/24/news/economy/tanning tax/
[35]	Cham, B.E., Daunter, B. and Evans, R. (1991) Topical treatment of malignant and premalignant skin cancers by very low concentrations of a standard mixture of solasodine glycosides. Cancer Letters 59, 183-192.
[36]	Cham, B.E. and Daunter, B. (1990) Topical treatment for pre-malignant and malignant skin cancers with Curaderm. Drugs of Today 26, 55-58.
[37]	Cham, B.E. (1994) Solasodine glycosides as anti-cancer agents: Pre- Clinical and clinical studies. Asia Pacif. J. Pharmacol. 9, 113-118.
[38]	Cham, B.E. (2007) Solasodine rhamnosyl glycosides in a cream formulation are effective for treating large and troublesome skin cancers. Res. J. Biol. Sci. 2(7), 749-761.
[39]	Cham, B.E. (2011) Topical Solasodine Rhamnosyl Glycosides Derived From the Eggplant Treats Large Skin Cancers: Two Case Reports. Int. J. Clin. Med. 2(4), 473-477.
[40]	Cham, B.E. (2012) Intralesion and Curaderm BEC topical Combination Therapies of Solasodine Rhamnosyl Glycosides Derived from the Eggplant or Devil’s Apple Result in Rapid Removal of Large Skin Cancers. Methods of Treatment Compared. Int. J. Clin. Med. 3(2), 115-124.
[41]	Cham, B.E. (2013) Topical Curaderm BEC5 Therapy for Periocular Nonmelanoma Skin Cancer: A Review of Clinical Outcomes. Int. J. Clin. Med. 4(5), 233-238.
[42]	Cham, B.E. (2013) Drug Therapy: Solamargine and other solasodine rhamnosyl glycosides as anticancer agents. Modern Chemotherapy. 2(2), 33-49.
[43]	Cham, B.E. (2014) A Review of Solasodine Rhamnosides Therapy for in-situ squamous cell carcinoma on the Penis. Brit. J. Med & Medical Res. 4(2): 621-631.

Cite This Article

Plain Text BibTeX RIS

APA Style

Aruba Cham, Kai Cham, Tania Chase, Bill Cham. (2015). A Standardized Plant Extract Containing a Target Compound is Acceptable as a Potent Therapeutic Entity: Relevance to BEC and Solamargine, a Topical Clinical Formulation CuradermBEC5. Journal of Cancer Treatment and Research, 3(2), 22-27. https://doi.org/10.11648/j.jctr.20150302.12

Copy | Download

ACS Style

Aruba Cham; Kai Cham; Tania Chase; Bill Cham. A Standardized Plant Extract Containing a Target Compound is Acceptable as a Potent Therapeutic Entity: Relevance to BEC and Solamargine, a Topical Clinical Formulation CuradermBEC5. J. Cancer Treat. Res. 2015, 3(2), 22-27. doi: 10.11648/j.jctr.20150302.12

Copy | Download

AMA Style

Aruba Cham, Kai Cham, Tania Chase, Bill Cham. A Standardized Plant Extract Containing a Target Compound is Acceptable as a Potent Therapeutic Entity: Relevance to BEC and Solamargine, a Topical Clinical Formulation CuradermBEC5. J Cancer Treat Res. 2015;3(2):22-27. doi: 10.11648/j.jctr.20150302.12

Copy | Download

@article{10.11648/j.jctr.20150302.12,
  author = {Aruba Cham and Kai Cham and Tania Chase and Bill Cham},
  title = {A Standardized Plant Extract Containing a Target Compound is Acceptable as a Potent Therapeutic Entity: Relevance to BEC and Solamargine, a Topical Clinical Formulation CuradermBEC5},
  journal = {Journal of Cancer Treatment and Research},
  volume = {3},
  number = {2},
  pages = {22-27},
  doi = {10.11648/j.jctr.20150302.12},
  url = {https://doi.org/10.11648/j.jctr.20150302.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.jctr.20150302.12},
  abstract = {New approaches to curb developmental and end-stage production expenses, whilst generating a safe and effective treatment for cancer, resulting in lower cost for the patient and healthcare system, are warranted. A bioassay-guided fractionation of a Solanum plant, S. sodomaeum, to a standardized extract can be classified as a new drug. It is shown that a specific standardized plant extract, BEC, containing a given concentration of a target efficacious and safe compound, solamargine, is an acceptable anticancer and less costly chemotherapeutic reality.},
 year = {2015}
}

Copy | Download

TY  - JOUR
T1  - A Standardized Plant Extract Containing a Target Compound is Acceptable as a Potent Therapeutic Entity: Relevance to BEC and Solamargine, a Topical Clinical Formulation CuradermBEC5
AU  - Aruba Cham
AU  - Kai Cham
AU  - Tania Chase
AU  - Bill Cham
Y1  - 2015/03/24
PY  - 2015
N1  - https://doi.org/10.11648/j.jctr.20150302.12
DO  - 10.11648/j.jctr.20150302.12
T2  - Journal of Cancer Treatment and Research
JF  - Journal of Cancer Treatment and Research
JO  - Journal of Cancer Treatment and Research
SP  - 22
EP  - 27
PB  - Science Publishing Group
SN  - 2376-7790
UR  - https://doi.org/10.11648/j.jctr.20150302.12
AB  - New approaches to curb developmental and end-stage production expenses, whilst generating a safe and effective treatment for cancer, resulting in lower cost for the patient and healthcare system, are warranted. A bioassay-guided fractionation of a Solanum plant, S. sodomaeum, to a standardized extract can be classified as a new drug. It is shown that a specific standardized plant extract, BEC, containing a given concentration of a target efficacious and safe compound, solamargine, is an acceptable anticancer and less costly chemotherapeutic reality.
VL  - 3
IS  - 2
ER  -

Copy | Download

Author Information

Aruba Cham

Department of Oncology, Australasian Medical Research, Port Vila, Republic of Vanuatu
Kai Cham

Research Section, Curaderm Global, Port Vila, Republic of Vanuatu
Tania Chase

Research Section, Curaderm Global, Port Vila, Republic of Vanuatu
Bill Cham

Department of Oncology, Australasian Medical Research, Port Vila, Republic of Vanuatu

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Aruba Cham, Kai Cham, Tania Chase, Bill Cham. (2015). A Standardized Plant Extract Containing a Target Compound is Acceptable as a Potent Therapeutic Entity: Relevance to BEC and Solamargine, a Topical Clinical Formulation CuradermBEC5. Journal of Cancer Treatment and Research, 3(2), 22-27. https://doi.org/10.11648/j.jctr.20150302.12

Copy | Download

ACS Style

Aruba Cham; Kai Cham; Tania Chase; Bill Cham. A Standardized Plant Extract Containing a Target Compound is Acceptable as a Potent Therapeutic Entity: Relevance to BEC and Solamargine, a Topical Clinical Formulation CuradermBEC5. J. Cancer Treat. Res. 2015, 3(2), 22-27. doi: 10.11648/j.jctr.20150302.12

Copy | Download

AMA Style

Aruba Cham, Kai Cham, Tania Chase, Bill Cham. A Standardized Plant Extract Containing a Target Compound is Acceptable as a Potent Therapeutic Entity: Relevance to BEC and Solamargine, a Topical Clinical Formulation CuradermBEC5. J Cancer Treat Res. 2015;3(2):22-27. doi: 10.11648/j.jctr.20150302.12

Copy | Download

@article{10.11648/j.jctr.20150302.12,
  author = {Aruba Cham and Kai Cham and Tania Chase and Bill Cham},
  title = {A Standardized Plant Extract Containing a Target Compound is Acceptable as a Potent Therapeutic Entity: Relevance to BEC and Solamargine, a Topical Clinical Formulation CuradermBEC5},
  journal = {Journal of Cancer Treatment and Research},
  volume = {3},
  number = {2},
  pages = {22-27},
  doi = {10.11648/j.jctr.20150302.12},
  url = {https://doi.org/10.11648/j.jctr.20150302.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.jctr.20150302.12},
  abstract = {New approaches to curb developmental and end-stage production expenses, whilst generating a safe and effective treatment for cancer, resulting in lower cost for the patient and healthcare system, are warranted. A bioassay-guided fractionation of a Solanum plant, S. sodomaeum, to a standardized extract can be classified as a new drug. It is shown that a specific standardized plant extract, BEC, containing a given concentration of a target efficacious and safe compound, solamargine, is an acceptable anticancer and less costly chemotherapeutic reality.},
 year = {2015}
}

Copy | Download

TY  - JOUR
T1  - A Standardized Plant Extract Containing a Target Compound is Acceptable as a Potent Therapeutic Entity: Relevance to BEC and Solamargine, a Topical Clinical Formulation CuradermBEC5
AU  - Aruba Cham
AU  - Kai Cham
AU  - Tania Chase
AU  - Bill Cham
Y1  - 2015/03/24
PY  - 2015
N1  - https://doi.org/10.11648/j.jctr.20150302.12
DO  - 10.11648/j.jctr.20150302.12
T2  - Journal of Cancer Treatment and Research
JF  - Journal of Cancer Treatment and Research
JO  - Journal of Cancer Treatment and Research
SP  - 22
EP  - 27
PB  - Science Publishing Group
SN  - 2376-7790
UR  - https://doi.org/10.11648/j.jctr.20150302.12
AB  - New approaches to curb developmental and end-stage production expenses, whilst generating a safe and effective treatment for cancer, resulting in lower cost for the patient and healthcare system, are warranted. A bioassay-guided fractionation of a Solanum plant, S. sodomaeum, to a standardized extract can be classified as a new drug. It is shown that a specific standardized plant extract, BEC, containing a given concentration of a target efficacious and safe compound, solamargine, is an acceptable anticancer and less costly chemotherapeutic reality.
VL  - 3
IS  - 2
ER  -

Copy | Download